Steven Cohen's MDGL Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 126,435 shares of Madrigal Pharmaceuticals, Inc. (MDGL) worth $73.63 M, representing 0.08% of the portfolio. First purchased in 2017-Q4, this long-term strategic position has been held for 26 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in MDGL, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2023, adding 172,900 shares. Largest reduction occurred in Q4 2023, reducing 172,900 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Madrigal Pharmaceuticals (MDGL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Madrigal Pharmaceuticals (MDGL) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +85,202 | Add 206.64% | 126,435 | $582.34 |
| Q3 2025 | -69,644 | Reduce 62.81% | 41,233 | $458.66 |
| Q2 2025 | +45,017 | Add 68.35% | 110,877 | $302.64 |
| Q1 2025 | +65,860 | New Buy | 65,860 | $331.23 |
| Q3 2024 | -40,958 | Sold Out | 0 | $0.00 |
| Q2 2024 | -52,613 | Reduce 56.23% | 40,958 | $280.16 |
| Q1 2024 | +93,571 | New Buy | 93,571 | $267.04 |
| Q4 2023 | -172,900 | Sold Out | 0 | $0.00 |
| Q3 2023 | +172,900 | New Buy | 172,900 | $146.04 |
| Q2 2023 | -3,993 | Sold Out | 0 | $0.00 |
| Q1 2023 | +3,993 | New Buy | 3,993 | $242.26 |
| Q4 2022 | -22,876 | Sold Out | 0 | $0.00 |
| Q3 2022 | +22,876 | New Buy | 22,876 | $65.00 |
| Q4 2021 | -30,100 | Sold Out | 0 | $0.00 |
| Q3 2021 | +30,100 | New Buy | 30,100 | $79.80 |
| Q2 2020 | -78,900 | Sold Out | 0 | $0.00 |
| Q1 2020 | +78,900 | New Buy | 78,900 | $66.76 |
| Q4 2019 | -30,521 | Sold Out | 0 | $0.00 |
| Q3 2019 | -27,379 | Reduce 47.29% | 30,521 | $86.24 |
| Q2 2019 | +37,133 | Add 178.81% | 57,900 | $104.80 |
| Q1 2019 | -32,233 | Reduce 60.82% | 20,767 | $125.25 |
| Q4 2018 | -41,800 | Reduce 44.09% | 53,000 | $112.72 |
| Q3 2018 | +94,800 | New Buy | 94,800 | $214.14 |
| Q2 2018 | -39,900 | Sold Out | 0 | $0.00 |
| Q1 2018 | -80,100 | Reduce 66.75% | 39,900 | $116.79 |
| Q4 2017 | +120,000 | New Buy | 120,000 | $91.79 |
Steven Cohen's Madrigal Pharmaceuticals Investment FAQs
Steven Cohen first purchased Madrigal Pharmaceuticals, Inc. (MDGL) in Q4 2017, acquiring 120,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Madrigal Pharmaceuticals, Inc. (MDGL) for 26 quarters since Q4 2017.
Steven Cohen's largest addition to Madrigal Pharmaceuticals, Inc. (MDGL) was in Q3 2023, adding 172,900 shares worth $25.25 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 126,435 shares of Madrigal Pharmaceuticals, Inc. (MDGL), valued at approximately $73.63 M.
As of the Q4 2025 filing, Madrigal Pharmaceuticals, Inc. (MDGL) represents approximately 0.08% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Madrigal Pharmaceuticals, Inc. (MDGL) was 172,900 shares, as reported at the end of Q3 2023.